Obsidian Therapeutics (NASDAQ:OBX) Stock Rating Upgraded by Zacks Research

Obsidian Therapeutics (NASDAQ:OBX) was upgraded by analysts at Zacks Research to a “hold” rating in a research report issued on Thursday,Zacks.com reports.

Other research analysts also recently issued reports about the stock. TD Cowen began coverage on shares of Obsidian Therapeutics in a research note on Thursday. They set a “buy” rating on the stock. Piper Sandler initiated coverage on Obsidian Therapeutics in a report on Wednesday. They issued an “overweight” rating and a $42.00 price objective on the stock. Two equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, Obsidian Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $42.00.

Obsidian Therapeutics Stock Down 3.0%

NASDAQ OBX opened at $27.50 on Thursday. Obsidian Therapeutics has a twelve month low of $23.00 and a twelve month high of $49.97.

Obsidian Therapeutics is a biotechnology company focused on developing engineered cell and gene therapies for cancer and other serious diseases. The company’s approach is designed to improve the safety, control and effectiveness of therapeutic proteins and genetic medicines by enabling their activity to be regulated inside the body.

Obsidian’s technology platform, known as cytoDRiVE, uses small-molecule-controlled genetic systems to modulate the expression or activity of therapeutic proteins.